HER3 的研究进展：从信号通路到靶向治疗 一、HER3 在受体酪氨酸激酶家族中的地位 HER3 是 HER/ErbB 家族受体酪氨酸激酶的重要成员，与 EGFR（HER1）、HER2 和 HER4 共同在细胞信号传导中发挥关键作用。与家族其他成员相比，HER3 的内在激酶活性较弱。然而，这并不影响 ...

2023年ASCO期间，百利天恒报告了全球首创的EGFR/HER3双抗ADC药物BL-B01D1的首次临床数据，139例患者整体评估的客观缓解率ORR达到45.3%，38例EGFR突变非小细胞肺癌患者的ORR更是高达63.2%，是迄今为止全球最优的数据。

Expert Rev Mol Diagn. 2008;8(4):417-434. Interestingly, cancers that co-overexpress EGFR and HER2 have a worse clinical outcome than those overexpressing either receptor alone. There is therefore ...

表 1. 第三代 EGFR-TKIs 进展的 EGFR 突变转移性 NSCLC 病例临床试验数据汇总 对于 HER2 突变或扩增 ... 如 TROP-2 和 HER3 ADC。 对于第三代 EGFR-TKIs 治疗后 ...

EGF receptor (EGFR) and HER2 are two members of the ErbB/HER-family of tyrosine-kinase receptors that are frequently altered in breast cancer and several other malignancies, which inspired the ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

Already-marketed HER2-targeting ADC Enhertu (trastuzumab ... Researchers have hypothesised that inhibiting EGFR and HER3 in tandem could lead to greater efficiency and also overcome resistance ...

HER3 is expressed in more than 80% of EGFR-mutant NSCLC ... Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in ...